Search clinical trials for: NXC-201 CAR-T

Total 1272 results

Nexcella Inc.

Not yet recruiting

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NEXICART-2)

Light Chain (AL) Amyloidosis

United States
Hadassah Medical Organization
Nexcella, Inc

Recruiting

NXC-201 (Formerly HBI0101) Multiple Myeloma

Dose Escalation and Safety

Israel
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Shanghai East Hospital
Bio4T2 LLC

Recruiting

Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors

Advanced Solid Tumor

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...

Terminated

Study of LUCAR-20S in Patients With R/R NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Shanghai East Hospital
Bio4T2 LLC

Active, not recruiting

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Bioray Laboratories
Wuhan Union Hospital, China; Zhejiang University; Institute of Hematology ＆ Blood...

Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
Chimeric Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

CAR-T Cell Immunotherapy | Glioma of Brain
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
University College, London

Enrolling by invitation

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

Autoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still Disease

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
University of California, San Francisco

Withdrawn

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Lymphoma | Leukemia | Plasma Cell Dyscrasia
City of Hope Medical Center
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Breast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
Chunrui Li
Nanjing IASO Biotechnology Co., Ltd

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM

Multiple Myeloma

China
Jiujiang University Affiliated Hospital
KAEDI

Withdrawn

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

Melanoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

China
Minerva Biotechnologies Corporation
City of Hope Medical Center

Recruiting

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

Metastatic Breast Cancer

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Reduction in Hypertrophic Skin Scarring

United States
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
The First Affiliated Hospital of Nanchang University

Unknown

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Rapa Therapeutics LLC
Medical College of Wisconsin

Recruiting

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Relapsed, Refractory Multiple Myeloma

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

CAR-T for R/R B-NHL

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30

China
First Affiliated Hospital of Zhejiang University

Unknown

Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China

Search clinical trials for: NXC-201 CAR-T

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations